{"disease":{"id":"generalized-myasthenia-gravis-gmg","name":"generalized myasthenia gravis gmg"},"drugs":{"marketed":[{"drug_id":"eculizumab-aeeb","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"nipocalimab","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07247279","title":"Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07284420","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT07294170","title":"ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT06759948","title":"An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Chongbo Zhao","has_results":false},{"nct_id":"NCT07215949","title":"Zilucoplan for Severe gMG Exacerbations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Miriam Freimer","has_results":false},{"nct_id":"NCT06764160","title":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07058298","title":"GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Daishi Tian","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}